Publikationen in Zusammenarbeit mit Forschern von Fudan University (31)

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

    The Lancet, Vol. 402, Núm. 10415, pp. 1835-1847

  3. Coronary angiography-derived index for assessing microcirculatory resistance in patients with non-obstructed vessels: The FLASH IMR study

    American Heart Journal, Vol. 263, pp. 56-63

  4. Country-level gender inequality is associated with structural differences in the brains of women and men

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 120, Núm. 20

  5. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022

    European Urology

  6. Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022

    European Journal of Cancer

  7. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

    The Lancet, Vol. 401, Núm. 10391, pp. 1853-1865

2022

  1. Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup

    The Lancet Oncology, Vol. 23, Núm. 8, pp. e374-e384

  2. Genetic variants associated with longitudinal changes in brain structure across the lifespan

    Nature neuroscience, Vol. 25, Núm. 4, pp. 421-432

  3. NSCLC Subtyping in Conventional Cytology: Results of the International Association for the Study of Lung Cancer Cytology Working Group Survey to Determine Specific Cytomorphologic Criteria for Adenocarcinoma and Squamous Cell Carcinoma

    Journal of Thoracic Oncology, Vol. 17, Núm. 6, pp. 793-805

2021

  1. Central data monitoring in the multicentre randomised SafeBoosC-III trial – a pragmatic approach

    BMC Medical Research Methodology, Vol. 21, Núm. 1

  2. Global Chronic Total Occlusion Crossing Algorithm: JACC State-of-the-Art Review

    Journal of the American College of Cardiology, Vol. 78, Núm. 8, pp. 840-853

  3. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  4. Nomenclature in nephrology: preserving ‘renal’ and ‘nephro' in the glossary of kidney health and disease

    Journal of Nephrology, Vol. 34, Núm. 3, pp. 639-648

  5. Resting distal to aortic pressure ratio and fractional flow reserve discordance affects the diagnostic performance of quantitative flow ratio: Results from an individual patient data meta-analysis

    Catheterization and Cardiovascular Interventions, Vol. 97, Núm. 5, pp. 825-832

  6. The International Association for the Study of Lung Cancer Global Survey on Programmed Death-Ligand 1 Testing for NSCLC

    Journal of Thoracic Oncology, Vol. 16, Núm. 4, pp. 686-696

2020

  1. A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee

    Journal of Thoracic Oncology, Vol. 15, Núm. 10, pp. 1599-1610

  2. Autoantibodies against type I IFNs in patients with life-threatening COVID-19

    Science, Vol. 370, Núm. 6515

  3. Establishment of a clinician-led guideline on the diagnosis and treatment of Hirayama disease using a modified Delphi technique

    Clinical Neurophysiology, Vol. 131, Núm. 6, pp. 1311-1319

  4. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19

    Science, Vol. 370, Núm. 6515